MobileIron Research Reveals 8 in 10 IT Leaders Want to Eliminate Passwords and Expect Mobile Devices to Become Primary Authentication to the Enterprise
27.6.2019 15:00:00 EEST | Business Wire | Press release
MobileIron (NASDAQ:MOBL) today revealed the results of a survey conducted with IDG, which found that enterprise users and security professionals alike are frustrated by the inefficiency and lax security of passwords for user authentication. With 90% of security professionals reporting to have seen unauthorized access attempts as a result of stolen credentials, it’s clear that the future of security requires a next generation of authentication that’s more secure.
Mobile devices are the best option for replacing passwords, as they remain at the center of enterprises in terms of where business is done, how access is given, and how authentication is done. In fact, the survey revealed that almost nine-in-ten (88%) security leaders believe that mobile devices will soon serve as digital ID to access enterprise services and data.
The survey, sponsored by MobileIron, polled 200 IT security leaders in the US, UK, Australia, and New Zealand working in a range of industries at companies with at least 500 employees. The aim was to discover the major authentication pain points facing enterprises.
“It’s time to say goodbye to passwords. They not only cause major frustrations for users and IT professionals, but they also pose major security risks,” said Rhonda Shantz, Chief Marketing Officer at MobileIron. “That’s why MobileIron is ushering in a new era of user authentication with a mobile ID and zero sign-on experience from any device, any OS, any location, to any service. With more and more users accessing apps and company data via their own mobile devices, it’s not only easier to leverage mobile devices than passwords for user authentication – it’s also much more secure.”
The perils of passwords:
- 90% of security pros have seen unauthorized access attempts as a result of stolen credentials.
- Security leaders estimate that they could reduce their risk of breach by almost half by eliminating passwords.
- Two out of every five (41%) of helpdesk tickets result from password or multi-factor authentication (MFA) lockout,
- Password lockout sentiment for end-users: 68% feel disrupted; 63% feel irritated; 62% feel frustrated; 62% feel that they have wasted time.
- Almost half (45%) of all end-users reuse personal and corporate passwords, which does not comport with security best-practices.
- Security leaders estimate that they could reduce their risk of breach by almost half (43%) simply by eliminating passwords.
- Almost every security leader (86%) would do away with passwords if they could.
- Almost three-in-four (72%) security leaders are actively looking to replace passwords.
The merits of mobile:
- Almost nine-in-ten (88%) security leaders believe that in the near future, mobile devices will serve as your digital ID to access enterprise services and data.
-
About two-in-five end-users (42%) need daily access to mobile business apps, but that number is expected to grow significantly in the next two years.
- Almost all organizations saw the use of business apps expand last year (85%).
- Almost all organizations expect to see continued expansion in the next 2 years (87%).
- Millennials are driving demand for broader access to business apps on mobile devices (94% vs. 73% non-Millennials).
MobileIron recently introduced a revolutionary zero sign-on experience built on the company’s leading unified endpoint management (UEM) platform and powered by the MobileIron Access solution. MobileIron’s platform allows for continuous enforcement and protection of data, both on the device and on the network, with comprehensive correlation between the critical signals for zero trust: user, device, apps, networks, and threats. Zero sign-on completely eliminates passwords as the method for user authentication, replacing single sign-on, which still requires at least one username and password.
To download a complimentary copy of the IDG survey results, please visit here.
About MobileIron
MobileIron is redefining enterprise security with the industry’s first mobile-centric, zero trust platform built on the foundation of unified endpoint management (UEM) to secure access and protect data across the perimeter-less enterprise. Over 17,000 customers, including the world’s largest financial institutions, intelligence agencies, and other highly regulated companies rely on MobileIron to enable a seamless and secure user experience by ensuring only authorized users, devices, apps, and services can access business resources. For more information, visit www.mobileiron.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190627005221/en/
Contact information
Becca Chambers
Head of Global Corporate Communications
bchambers@mobileiron.com
650.722.1647
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
